Inhibition of miRNA-1-Mediated Inflammation and Autophagy by Astragaloside IV Improves Lipopolysaccharide-Induced Cardiac Dysfunction in Rats

References

• Liu J, Chen HB, Guo BL, et al. Study of the relationship between genetics and geography in determining the quality of Astragali Radix. Biol Pharm Bull. 2011;34:1404. doi:10.1248/bpb.34.1404
   PubMed Web of Science ®Google Scholar
• Jin C, Dai RH. [Effect of Astragalus membranaceus on erythrocyte sodium content and sodium transport in the coronary heart disease]. Zhong Xi Yi Jie He Za Zhi. 1991;11:651. Chinese.
   PubMedGoogle Scholar
• Yang QY, Lu S, Sun HR. [Effects of Astragalus on cardiac function and serum tumor necrosis factor-alpha level in patients with chronic heart failure]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010;30:699. Chinese.
   PubMedGoogle Scholar
• Huang ZQ, Qin NP, Ye W. [Effect of Astragalus membranaceus on T-lymphocyte subsets in patients with viral myocarditis]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1995;15:328. Chinese.
   PubMedGoogle Scholar
• Xu GH, Yuan L, Li Y, et al. [Clinical observation of Astragalus injection in treatment of renal injury in patients with primary hypertension]. Zhong Xi Yi Jie He Xue Bao. 2008;6:530. Chinese. doi:10.3736/jcim20080519
   PubMedGoogle Scholar
• Zhang Y, Mao XD, Cao AL, et al. Astragaloside IV prevents endothelial dysfunction by improving oxidative stress in streptozotocin-induced diabetic mouse aortas. Exp Ther Med. 2021;22:1197. doi:10.3892/etm.2021.10631
   PubMed Web of Science ®Google Scholar
• Yu C, Zhang J, Li X, et al. Astragaloside IV-induced Nrf2 nuclear translocation ameliorates lead-related cognitive impairments in mice. Biochim Biophys Acta Mol Cell Res. 2021;1868:118853. doi:10.1016/j.bbamcr.2020.118853
   PubMed Web of Science ®Google Scholar
• Yao J, Fang X, Zhang C, et al. Astragaloside IV attenuates hypoxia-induced pulmonary vascular remodeling via the Notch signaling pathway. Mol Med Rep. 2021;23:1.
   Web of Science ®Google Scholar
• Sun C, Zeng G, Wang T, et al. Astragaloside IV ameliorates myocardial infarction induced apoptosis and restores cardiac function. Front Cell Dev Biol. 2021;9:671255. doi:10.3389/fcell.2021.671255
   PubMed Web of Science ®Google Scholar
• Ebner N, Foldes G, Schomburg L, et al. Lipopolysaccharide responsiveness is an independent predictor of death in patients with chronic heart failure. J Mol Cell Cardiol. 2015;87:48. doi:10.1016/j.yjmcc.2015.07.029
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Toldo S, Mezzaroma E, et al. Targeting interleukin-1 in heart disease. Circulation. 2013;128(17):1910. doi:10.1161/CIRCULATIONAHA.113.003199
   PubMed Web of Science ®Google Scholar
• Zhang X, Li M, Wang H. Astragaloside IV alleviates the myocardial damage induced by lipopolysaccharide via the toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-kappaB)/proliferator-activated receptor alpha (PPARalpha) signaling pathway. Med Sci Monit. 2019;25:7158. doi:10.12659/MSM.916030
   PubMed Web of Science ®Google Scholar
• Wang SG, Xu Y, Xie H, et al. Astragaloside IV prevents lipopolysaccharide-induced injury in H9C2 cardiomyocytes. Chin J Nat Med. 2015;13:127. doi:10.1016/S1875-5364(15)60016-4
   PubMed Web of Science ®Google Scholar
• Zhao P, Wang Y, Zeng S, et al. Protective effect of astragaloside IV on lipopolysaccharide-induced cardiac dysfunction via downregulation of inflammatory signaling in mice. Immunopharmacol Immunotoxicol. 2015;37(5):428. doi:10.3109/08923973.2015.1080266
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang Y, Fan Y. Eupafolin ameliorates lipopolysaccharide-induced cardiomyocyte autophagy via PI3K/AKT/mTOR signaling pathway. Iran J Basic Med Sci. 2019;22:1340. doi:10.22038/ijbms.2019.37748.8977
   PubMed Web of Science ®Google Scholar
• Zhang T, Wang H, Lu M, et al. Astragaloside IV prevents myocardial hypertrophy induced by mechanical stress by activating autophagy and reducing inflammation. Am J Transl Res. 2020;12:5332.
   PubMed Web of Science ®Google Scholar
• Pei C, Wang F, Huang D, et al. Astragaloside IV protects from PM2.5-induced lung injury by regulating autophagy via inhibition of PI3K/Akt/mTOR signaling in vivo and in vitro. J Inflamm Res. 2021;14:4707. doi:10.2147/JIR.S312167
   PubMed Web of Science ®Google Scholar
• Luo LF, Qin LY, Wang JX, et al. Astragaloside IV attenuates the myocardial injury caused by adriamycin by inhibiting autophagy. Front Pharmacol. 2021;12:669782. doi:10.3389/fphar.2021.669782
   PubMed Web of Science ®Google Scholar
• Zhu Y, Qian X, Li J, et al. Astragaloside-IV protects H9C2 (2-1)cardiomyocytes from high glucose-induced injury via miR-34a-mediated autophagy pathway. Artif Cells Nanomed Biotechnol. 2019;47:4172. doi:10.1080/21691401.2019.1687492
   PubMed Web of Science ®Google Scholar
• Sayed D, Hong C, Chen IY, et al. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res. 2007;100:416. doi:10.1161/01.RES.0000257913.42552.23
   PubMed Web of Science ®Google Scholar
• Perez-Cremades D, Mompeon A, Vidal-Gomez X, et al. Role of miRNA in the regulatory mechanisms of estrogens in cardiovascular ageing. Oxid Med Cell Longev. 2018;2018:6082387. doi:10.1155/2018/6082387
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12:735. doi:10.1016/S0960-9822(02)00809-6
   PubMed Web of Science ®Google Scholar
• Yang B, Lin H, Xiao J, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med. 2007;13:486. doi:10.1038/nm1569
   PubMed Web of Science ®Google Scholar
• Bostjancic E, Zidar N, Stajner D, et al. MicroRNA miR-1 is up-regulated in remote myocardium in patients with myocardial infarction. Folia Biol. 2010;56:27.
   PubMed Web of Science ®Google Scholar
• Shan ZX, Lin QX, Fu YH, et al. Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochem Biophys Res Commun. 2009;381:597. doi:10.1016/j.bbrc.2009.02.097
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhang L, Wang Y, et al. Astragaloside IV attenuates renal fibrosis through repressing epithelial-to-mesenchymal transition by inhibiting microRNA-192 expression: in vivo and in vitro studies. Am J Transl Res. 2019;11:5029.
   PubMed Web of Science ®Google Scholar
• Tomaniak M, Sygitowicz G, Blaszczyk O, et al. miR-1, miR-21, and galectin-3 in hypertensive patients with symptomatic heart failure and left ventricular hypertrophy. Kardiol Pol. 2018;76:1009. doi:10.5603/KP.2018.0117
   PubMed Web of Science ®Google Scholar
• Mei M, Tang F, Lu M, et al. Astragaloside IV attenuates apoptosis of hypertrophic cardiomyocyte through inhibiting oxidative stress and calpain-1 activation. Environ Toxicol Pharmacol. 2015;40:764. doi:10.1016/j.etap.2015.09.007
   PubMed Web of Science ®Google Scholar
• Zhang N, Feng H, Liao HH, et al. Myricetin attenuated LPS induced cardiac injury in vivo and in vitro. Phytother Res. 2018;32:459. doi:10.1002/ptr.5989
   PubMed Web of Science ®Google Scholar
• Yang J, Wang HX, Zhang YJ, et al. Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF-small ka, CyrillicB signaling pathway in isoproterenol-induced myocardial hypertrophy. J Ethnopharmacol. 2013;150:1062. doi:10.1016/j.jep.2013.10.017
   PubMed Web of Science ®Google Scholar
• Lu M, Leng B, He X, et al. Calcium sensing receptor-related pathway contributes to cardiac injury and the mechanism of astragaloside IV on cardioprotection. Front Pharmacol. 2018;9:1163. doi:10.3389/fphar.2018.01163
   PubMed Web of Science ®Google Scholar
• Lu M, Tang F, Zhang J, et al. Astragaloside IV attenuates injury caused by myocardial ischemia/reperfusion in rats via regulation of toll-like receptor 4/nuclear factor-kappaB signaling pathway. Phytother Res. 2015;29:599. doi:10.1002/ptr.5297
   PubMed Web of Science ®Google Scholar
• Lu M, Wang H, Wang J, et al. Astragaloside IV protects against cardiac hypertrophy via inhibiting the Ca2+/CaN signaling pathway. Planta Med. 2014;80:63. doi:10.1055/s-0033-1360129
   PubMed Web of Science ®Google Scholar
• Luo Y, Fan C, Yang M, et al. CD74 knockout protects against LPS-induced myocardial contractile dysfunction through AMPK-Skp2-SUV39H1-mediated demethylation of BCLB. Br J Pharmacol. 2020;177:1881. doi:10.1111/bph.14959
   PubMed Web of Science ®Google Scholar
• Pang J, Peng H, Wang S, et al. Mitochondrial ALDH2 protects against lipopolysaccharide-induced myocardial contractile dysfunction by suppression of ER stress and autophagy. Biochim Biophys Acta Mol Basis Dis. 2019;1865:1627. doi:10.1016/j.bbadis.2019.03.015
   PubMed Web of Science ®Google Scholar
• Wang Q, Yang X, Song Y, et al. Astragaloside IV-targeting miRNA-1 attenuates lipopolysaccharide-induced cardiac dysfunction in rats through inhibition of apoptosis and autophagy. Life Sci. 2021;275:119414. doi:10.1016/j.lfs.2021.119414
   PubMed Web of Science ®Google Scholar
• Sui YB, Wang Y, Liu L, et al. Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway. Pharm Biol. 2019;57:48. doi:10.1080/13880209.2019.1569697
   PubMed Web of Science ®Google Scholar
• Dong Z, Zhao P, Xu M, et al. Astragaloside IV alleviates heart failure via activating PPARalpha to switch glycolysis to fatty acid beta-oxidation. Sci Rep. 2017;7:2691. doi:10.1038/s41598-017-02360-5
   PubMed Web of Science ®Google Scholar
• Xu XL, Chen XJ, Ji H, et al. Astragaloside IV improved intracellular calcium handling in hypoxia-reoxygenated cardiomyocytes via the sarcoplasmic reticulum Ca-ATPase. Pharmacology. 2008;81:325. doi:10.1159/000121335
   PubMed Web of Science ®Google Scholar
• Tang B, Zhang JG, Tan HY, et al. Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure. Biosci Rep. 2018;38. doi:10.1042/BSR20171036
   Web of Science ®Google Scholar
• Liu T, Yang F, Liu J, et al. Astragaloside IV reduces cardiomyocyte apoptosis in a murine model of coxsackievirus B3-induced viral myocarditis. Exp Anim. 2019;68:549. doi:10.1538/expanim.19-0037
   PubMed Web of Science ®Google Scholar
• Zhao Z, Wang W, Wang F, et al. Effects of Astragaloside IV on heart failure in rats. Chin Med. 2009;4:6. doi:10.1186/1749-8546-4-6
   PubMedGoogle Scholar
• Cheng S, Yu P, Yang L, et al. Astragaloside IV enhances cardioprotection of remote ischemic conditioning after acute myocardial infarction in rats. Am J Transl Res. 2016;8:4657.
   PubMed Web of Science ®Google Scholar
• Tang Y, Zheng J, Sun Y, et al. MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int Heart J. 2009;50:377. doi:10.1536/ihj.50.377
   PubMed Web of Science ®Google Scholar